EuGeni, page-1769

First 1769 Last

Share
Profile

Follow
TropFreedom

409 Posts.

200

23/10/21

12:20

Post #: 57018352
Share

Originally posted by semi retired: ↑

Dear O 'Dear , the second approved test in the UK Global Access Diagnostics is Roche's Covid-19 test that was booted from Germany , they got in under Emergency use authorisation by FDA then into the UK , won't be long till Roche's will be booted from UK also with that poor sensitivity, Anteotec's RAT test looks the best test fit for purpose , compare to Roche that spent $12 billion on R&D , Anteotech has done very well indeed .

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche, Abbott COVID Antigen Tests Just So-So in Real-World Data

— "Unsatisfactory" for screening asymptomatic people, say German lab professionals

by John Gever, Contributing Writer, MedPage Today August 9, 2021

Sensitivities for the antigen tests were especially low -- under 40% -- when the individuals had no comorbidities, were asymptomatic (just 23% for the Abbott test and barely 30% for Roche's), or had previously recovered from COVID.

Among 2,215 "all-comers" tested at a German diagnostics lab, with 338 ultimately showing positive results with PCR testing, Roche's SD Biosensor and Abbott's Panbio rapid antigen tests showed overall sensitivities of 60.4% and 56.8%, respectively, reported Christoph Wertenauer, of Synlab GmbH in Augsburg and the University of Heidelberg in Mannheim, and colleagues.

https://www.medpagetoday.com/infectiousdisease/covid19/93961

March 2020
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care

https://diagnostics.roche.com/globa...symptomatic-and-asymptomatic-individuals.html

Expand

Semi thanks for the informative post again. ADO is so very small in size compared to Roche and Abbott. It certainly would be amazing if we can produce a far superior RAT which starts to take away market share! The question is how much will ADO be able to produce in a global pandemic.......

ADO Price at posting: 25.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

CU6

Clarity progresses SECuRE trial with positive safety results

3 stocks with antimony news on Thursday

NEC

Nine Entertainment announces its CEO is stepping down – on an ex-divvy day

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

BRX

Belararox to grow copper footprint in Botswana with 4,286 square km tenure

MTM

Forget gallium: MTM says it's extracted gold from e-waste

SS1

Sun Silver confirms high-grade extension theory at Maverick Springs with 79.6 g/t intercept

ASX Market Open: Local bourse to trade green | Thursday September 12